Introduction
Until recently only six gene regions were commonly accepted as associated with type I diabetes (T1D), human leukocyte antigen (HLA) class II, Insulin (INS), CTLA4, PTPN22, IL2RA and IFIH1. The pace of discovery of genetic associations with T1D has now accelerated. Owing to largescale genome-wide association studies (GWAS), as well as candidate gene studies, the total number of confirmed loci, including the MHC region, is now 43 (www.T1DBase. org). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Despite the evidence of association for these loci being replicated, the localization of causal genes and variants is ongoing and the mechanisms by which the variants influence T1D risk have yet to be determined. For instance, the HLA class II region (and the HLA class II genes) has been accepted as the major T1D locus for over 20 years, 16, 17 yet only recently has definitive evidence been published and replicated for additional independent effects of the HLA class I genes (HLA-A and HLA-B).
1,18
The second major T1D susceptibility locus is INS. In addition to the recognized INS VNTR, two equally likely candidates have been identified, rs689 (À23HphI) and rs3842753. 19 To date, no study has been published that can convincing distinguish these two single-nucleotide polymorphisms (SNPs) with respect to impact on T1D risk although expression studies point to the VNTR as the causal variant. The rs689 SNP is an accurate proxy for the two main classes of VNTR alleles.
As PTPN22 was first identified as associated with T1D, 13, 20 the association of the primary SNP, rs2476601 (C1858T encoding R620W) has been replicated in many sample collections. 21, 22 Additional research has focused on establishing whether rs2476601 represents the only associated variant in the region. Convincing evidence of an alternative or independent association with other SNPs in PTPN22 has yet to be reported. 23 The association of IL2RA with T1D was established using a tag SNP approach 24 and replicated in an independent study. 25 Three independent associations have subsequently been identified in the region 4, 10, 26 and are dependent on the arrangement of alleles on the haplotype background. 27 The strongest association is with a group of eight SNPs. 4 The original study used rs41295061 to tag this effect 4 but more recently rs12722495 has been shown to be a more effective tag, with an odds ratio (OR) of 0.62. 10 The second independent association is with a group of three SNPs, with rs11594656 the most strongly associated of the three. 4 The third association is with a single SNP that does not appear to be in linkage disequilibrium (LD) with any other SNPs. 26, 27 The locus is also associated with multiple sclerosis susceptibility. 26 The region on chromosome 2q33 containing CTLA4 has been recognized as a T1D susceptibility gene region since 1996. 2 Although rs231806 (MH30), rs7565213 (JO30) and rs3087243 (CT60) are the most associated variants, the high LD across the region and lack of thorough resequencing data have precluded further refinement of the identity or location of the causal variant. 28 With the advent of high throughput genotyping technologies, there has been an explosion in GWAS, and identification of additional T1D susceptibility loci, 5, 8, 29 some of which have been replicated. 5, 6 In the first GWAS published in diabetes, 8 convincing support was obtained for a T1D susceptibility region on chromosome 2q24.3 containing four genes, including the functional candidate gene IFIH1. IFIH1 encodes the intracellular receptor MDA5 for RNA from picornaviruses, one of which (coxsackie virus) has been implicated in T1D. Subsequently, additional GWAS analyses identified four regions that have been confirmed (12q13, 12q24, 16p13 and 18p11), bringing the non-HLA total to nine. Follow-up studies from these initial GWAS, new GWAS and tests of candidate SNPs associated in other autoimmune diseases, means 40 non-HLA loci show convincing evidence of association with T1D. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Other studies have claimed new gene associations with T1D, but the effects reported and the sample sizes used are very often small and consequently these other studies were underpowered. 30 The Type I Diabetes Genetics Consortium (T1DGC) combined nine collections of affected sib-pair (ASP) families (four recruited specifically for the T1DGC) and have selected 16 putative T1D loci, in addition to the five established non-HLA loci (INS, CTLA4, PTPN22, IL2RA, IFIH1) to test for association with T1D. The results from 19 of these loci are reported here. This combined sample set of 2300 ASP families is powered at 80% to find effect sizes as low as 1.2 with a minor allele frequency (MAF) of 0.25, assuming a multiplicative model, at a ¼ 0.0024.
Results
SNPs from the 19 genes for which we had data access were analyzed for association with T1D. All results from these analyses have been provided to the T1DGC (http://www.t1dgc.org) and are available for viewing through T1DBase (http://www.T1DBase.org). The majority of SNPs were genotyped on two platforms (Illumina and Sequenom); however, the intensity data were not available for either platform (so cluster plots could not be examined). All SNP genotype data were tested for quality control (QC) metrics within each source (genotyping platform) separately. The QC metrics used were tests for deviations from Hardy Weinberg equilibrium, low MAF, excessive misinheritance, low call rate and high sample failure rate (see Materials and methods in this paper and the description of Coordinating Center QC in Brown et al., 31 this volume). These procedures should minimize the number of SNPs with poor clusters in the dataset and, therefore, maximize the power of the study to detect true effects.
The SNPs that failed QC were platform dependent: 57 SNPs failed these metrics on Illumina and 64 SNPs failed on Sequenom. For any SNP with evidence of association with T1D, consistency across platforms was required for the observed association to be accepted (because of the lack of intensity information). Hence, two analyses were performed, the first in the Illumina dataset and the second in the Sequenom dataset. Associations were considered significant if Po0.0024 on both the platforms. This level of confidence was achieved for the five established loci (INS, CTLA4, PTPN22, IL2RA and IFIH1) but not for any of the remaining 14 candidate genes/ regions.
Insulin
Twenty-one SNPs were genotyped in the INS gene region. Twelve SNPs were successfully genotyped on both Sequenom and Illumina platforms; four SNPs were unique to Illumina and four unique to Sequenom. In addition, rs689 (À23HphI) was genotyped in all cohorts except the Danish using a reverse dot-plot method. 32 Thirteen SNPs from Sequenom and 10 from Illumina were significantly associated with T1D (Po0.0024) including the 8 SNPs common to both platforms (Table 1;  Supplementary Table 1 ). The three most strongly associated SNPs were rs689 (P ¼ 3.8 Â 10
) and rs3842748 (P ¼ 2.3 Â 10 À24 ). These three SNPs were in high LD (D 0 X0.94 and r 2 X0.69) in parents not known to have T1D. The effects because of rs3842748, rs689 and rs3842753 were distinguished using stepwise logistic regression. A model with either rs3842753 or rs689 could not be improved by addition of rs3842748 (minimum P ¼ 0.4857), so the association at rs3842748 could be explained by either rs689 or rs3842753. However, the associations at rs689 and rs3842753 could not be distinguished (P ¼ 0.1366 for addition of rs3842753 to rs689 in a logistic regression model; similarly for the addition of rs689 to rs3842753, P ¼ 0.0057; Table 1 ). These results are consistent with earlier work. 19 No evidence of sex-specific effects was observed at rs689 (P ¼ 0.63); however, there was evidence of an age-at-diagnosis effect at rs689 (P ¼ 0.001). The average age-at-diagnosis of individuals homozygous for the A allele at rs689 was 11.4 year, whereas homozygosity for the T allele (minor allele at rs689) was T1D protective, resulting in an increased average-age-at-diagnosis of 13.1 year. The median age-at-diagnosis within the T1DGC ASP families was 10 year, with an inter-quartile range of 5-15 year. The frequency of the protective T allele increases across each of the age-at-diagnosis quartiles 
IL2RA
A total of 69 SNPs were genotyped in the IL2RA region. Fifty-five were successful on Sequenom, 56 were successful on Illumina and 52 were common to both platforms. Four SNPs were associated with T1D in either the Sequenom data or the Illumina data (Table 2; Figure 1 ). The IL2RA SNP, rs3118470, was the most strongly associated SNP in the Sequenom data (P S ¼ 0.0009) and was significantly associated in the Illumina data (P I ¼ 0.0051, where P S and P I represent P values from the Sequenom and Illumina data, respectively). The IL2RA SNP rs12251307 was the most associated SNP in the Illumina dataset (P I ¼ 0.0006) but not in the Sequenom data (P S ¼ 0.0304).
Using rs12251307 as the most associated SNP in IL2RA, all other SNPs were added in a step-wise manner to the regression model to test for additional independent associations. No additional associations reached statistical significance (Table 2 ). Three independent effects in the IL2RA region have been reported earlier. 4, 10, 26, 27 We are well powered to detect the strongest association in the region, which has an OR ¼ 0.62. The most associated SNP in the current report, rs12251307, is in LD with rs41295061 (r 2 ¼ 0.71), 4 a SNP that tags the strongest association in the region. In the earlier report, 4 the effect of rs12251307 did not improve a model with rs41295061, suggesting that rs12251307 serves as a surrogate for the most associated SNP in the region and is not independent of rs41295061. (The effect itself could not be directly assessed in the T1DGC families, as neither rs12722495 nor rs41295061 were genotyped.) No evidence of association was obtained with rs11594656 (Table 2) , which marks the second weaker association in the region (OR ¼ 0.88). However, this is probably because of a lack of power, we had just 31% power to detect the second effect in the T1DGC families, with an OR ¼ 0.88. The third association, with rs2104286, which again the T1DGC families are not powered to detect, does not have any SNPs in LD with it 27 but was genotyped in the T1DGC families. No evidence of association with T1D was obtained with rs2104286, once the effect of rs12251307 Abbreviations: CI, confidence interval; I, Illumina; MAF, minor allele frequency; N, number; NA, not available; NC, number of chromosomes; P 1df , P value for association assuming a multiplicative model (see Materials and methods); P 2df , P value for association assuming no specific mode of inheritance (see Materials and methods); Prs696, P value for addition of the locus to a conditional logistic regression model that includes rs696; P rs3842753 , P value for addition of the locus to a conditional logistic regression model that includes rs3842753; RR, relative risk; S, Sequenom; SNP, single-nucleotide polymorphism; T, TaqMan; T1D, type I diabetes. Abbreviations: CI, confidence interval; I, Illumina; MAF, minor allele frequency; N, number; NA, not available; NC, number of chromosomes; P 1df , P value for association assuming a multiplicative model (see Materials and methods); P 2df , P value for association assuming no specific mode of inheritance (see Materials and methods); Padd, P value for addition of the locus to a conditional logistic regression model that includes rs12251307; RR, relative risk; S, Sequenom; SNP, single-nucleotide polymorphism; T1D, type I diabetes.
was included in the model (P ¼ 0.03, Table 2 ). In addition, there was no strong evidence for a sex-specific effect (minimum P ¼ 0.006) or an age-at-diagnosis effect (minimum P ¼ 0.07) with rs2104286.
PTPN22
Twenty-eight SNPs were genotyped in the PTPN22 region, 23 were successfully genotyped on Sequenom and 24 on Illumina, with 20 SNPs common to both platforms. Fifteen of these common SNPs in PTPN22 were significantly associated with T1D (Po0.0024, Table 3 ). Two additional SNPs were associated with T1D using Illumina data, rs1217395 and rs1217418 (rs1217418 was not associated in the Sequenom data). The most associated PTPN22 SNP in the T1DGC data was rs2476601 (P S ¼ 6.5 Â 10 À20 and P I ¼ 6.9 Â 10
À17
), in agreement with earlier studies. 23 This SNP represents a nonsynonymous amino acid change from arginine to Abbreviations: CI, confidence interval; I, Illumina; MAF, minor allele frequency; N, number; NA, not available; NC, number of chromosomes; P 1df , P value for association assuming a multiplicative model (see Materials and methods); P 2df , P value for association assuming no specific mode of inheritance (see Materials and methods); P add , P value for addition of the locus to a conditional logistic regression model that includes rs12251307; RR, relative risk; S, Sequenom; T1D, type I diabetes.
tryptophan at position 620 (R620W). Evidence for an additional, independent effect of rs1539438 was detected in the Illumina data (P I ¼ 0.0007), although this SNP did not reach significance in the Sequenom data (P S ¼ 0.009, . The effect of rs1539438 was not independent of rs2476601 (P ¼ 0.12) in this larger, sample set that had greater power than the T1DGC family samples. There was no evidence for sex-specific effects of rs2476601 (P40.09), in contrast to reports in smaller cohorts in the literature. 33, 34 Similarly, there was no significant evidence of age-at-diagnosis effects (P40.11).
IFIH1
Six SNPs were successfully genotyped in the IFIH1 region on both platforms. Two of these SNPs were significantly associated across both platforms ( Table 4) . The most strongly associated SNP was rs1990760 (P I ¼ 0.0002, P S ¼ 0.0001), the nonsynonymous (A946T) SNP associated earlier with T1D. 8 There was no evidence for additional associations that were independent of rs1990760 (minimum P ¼ 0.03, Table 4 ). These results are consistent with an earlier report that found rs1990760 was the most strongly associated SNP in the region but could not distinguish its effect from three other SNPs (rs2068330, rs2111485 and rs984971) that were in LD with it. 8 In the T1DGC family data, rs984971 was not significantly associated with T1D. In the Sequenom data, however, there was little difference in association among rs2068330, rs2111485 or rs1990760. Thus, any of three IFIH1 SNPs could nominally be chosen as the 'best' SNP. Similarly, although none of the SNPs improve a model including rs1990760, the rs1990760 SNP does not improve a model including either rs2068330 or rs2111485. The rs2068330 SNP is not associated in the Illumina data and, therefore, does require further investigation and should be re-genotyped using alternative technologies such as TaqMan. Additionally, rs1990760 and rs2111485 could not be distinguished in either the Sequenom data or the Illumina data. No evidence of sex-specific effects (minimum P ¼ 0.26) or of age-at-diagnosis effects (minimum P ¼ 0.04) was found at rs1990760.
CTLA4
Twenty-four SNPs were genotyped in the CTLA4 region, 21 SNPs were successfully genotyped on both platforms and one SNP (rs3087243) passed QC on Illumina. Only two SNPs (rs1427676 and rs231727), in strong LD with each other (r 2 ¼ 0.99 and D 0 ¼ 1.00) were significantly associated with T1D (Table 5) . Hence, when one of these two SNPs was included in the regression model, no additional independent associations were obtained (P40.02, Table 5 ).
Previously, the effects of two SNP regions 5 0 and 3 0 of CTLA4 (SNPs rs3087243, rs231806 and rs7565213) were found to be indistinguishable. 28 Of these SNPs, only rs3087243 was genotyped in the T1DGC ASP family collection, although no evidence of association with T1D was observed. However, it has been shown that the CTLA4 effect is smaller in ASP families compared with isolated cases (relative risk B1.15 in families compared to OR B1.2 in cases and controls). 28, 35, 36 Thus, the statistical power to observe the CTLA4 effect in the T1DGC ASP families is only 45% for a ¼ 0.0024, limiting the ability to detect specific CTLA4 effects.
Other genes and regions Twelve SNPs were successfully genotyped with both Sequenom and Illumina in IRS1 and two additional SNPs were genotyped with Illumina. None of the SNPs, however, were significantly associated with T1D (minimum P ¼ 0.03, Table 6 ). Only one SNP (rs2929366) was genotyped at EFHB, and this SNP was not significantly associated with T1D in either the Sequenom or Illumina data (P40.15, Table 6 ).
Previously, evidence was reported that a nonsynonymous SNP at CAPSL (rs1445898) could be associated with T1D. 5 The region was also associated in a separate Abbreviations: CI, confidence interval; I, Illumina; MAF, minor allele frequency; N, number; NA, not available; NC, number of chromosomes; P 1df , P value for association assuming a multiplicative model (see Materials and methods); P 2df , P value for association assuming no specific mode of inheritance (see Materials and methods); P add , P value for addition of the locus to a conditional logistic regression model that includes rs1990760; P b , P value for addition of rs1990760 to a conditional logistic regression model that includes the listed locus; RR, relative risk; S, Sequenom; T1D, type I diabetes.
population. 37 In the T1DGC ASP families, which are less well powered than the original report, there was no evidence supporting this association (minimum P ¼ 0.29).
In addition, no evidence of association was observed for rs9127 a SNP in the 3 0 downstream sequence of LNPEP on chr5q13 (Q7Z4C4(5Q)), minimum P ¼ 0.32, Table 6 ). Three interleukin genes associated earlier with T1D were evaluated in the T1DGC ASP family collection. In contrast to a small underpowered study 38 but in agreement with a larger better powered study, 39 no evidence of association was obtained for IL13, IL4 or IL4R SNPs with T1D (minimum P ¼ 0.04, Table 6 ). Twenty-seven SNPs were genotyped in the IL12B region, 22 were successfully genotyped on both the platforms. The SNP rs17875324 was genotyped with Sequenom and SNPs rs2569253 and rs3212227 were genotyped with Illumina. Several underpowered studies have reported association at the IL12B SNP, rs3212227, with the effect seen in cases 16 year and over. 40 However, the two largest studies to date, one with 2873 families and the other with 4321 T1D cases and 4711 controls, failed to confirm the association. 30, 41 Specifically, the case-control study did not obtain evidence of an ageat-diagnosis effect. 30 None of the SNPs genotyped in the T1DGC ASP families were associated at the significance threshold set for this study (Pp0.0024). For the previously reported SNP rs3212227, there was no evidence of association with T1D in the T1DGC ASP families (P ¼ 0.82). There was also no evidence of age-at-diagnosis effects (minimum P ¼ 0.17). We note that the IL12B SNP, rs17056704 just misses our threshold of P ¼ 0.003. This SNP failed QC in HapMap and has not been typed in the JDRF/WT Diabetes and Inflammation Laboratory's case-control samples. No association was found at SUMO4 with T1D at any of the 15 SNPs genotyped (minimum P ¼ 0.09). This result in the T1DGC families is in agreement with a previous well-powered casecontrol analysis. 42 Ten SNPs were genotyped in the PAX4 region, seven of which were successful on both the platforms. None were associated with T1D (Table 6) , which is in agreement with several reports in the literature. [43] [44] [45] Forty SNPs were genotyped in the VDR region, 27 were successfully typed on both the platforms with four additional SNPs successful on Illumina and three additional SNPs on Sequenom. There was no evidence of association at any of these SNPs (minimum P ¼ 0.0224, Table 6 ), consistent with other studies. 46 No evidence supporting sex-specific effects (minimum P ¼ 0.07) or age-at-diagnosis effects (minimum P ¼ 0.11) was obtained. Others have reported protective effects of a specific vitamin D receptor (VDR) haplotype (rs731236-rs7975232-rs10735810). 47 This result was in contrast to other reports. 48 As rs7975232 failed on both the platforms, two SNP haplotypes of rs731236 and rs10735810 were constructed. No evidence supporting an association with T1D (P ¼ 0.10) was obtained. Thus, the T1DGC ASP family data are consistent with a meta-analysis of T1D-VDR associations that concluded there was no evidence for association of VDR and T1D. 49 Ten of 11 SNPs in the OAS1 region were successfully genotyped, 9 of which were common to both platforms. No evidence of association with T1D was observed for any of these SNPs (Table 6 ). In the T1DGC families, the absence of association was in agreement with a wellpowered study, 50 but not with other smaller underpowered studies. 51, 52 The SNP reported earlier to have the strongest association (rs10774671) was not associated in these data (P ¼ 0.50). In the CEACAM21 region, the most associated SNP (rs2302188) was genotyped, but no evidence of association with T1D was obtained (P ¼ 0.07). Six SNPs in FOXP3 were genotyped and analyzed for association with T1D. No evidence of association was obtained (minimum P ¼ 0.26), in agreement with two smaller studies. 63 ). An important conclusion from this work is that, when analyzing high throughput genotype data, genotyping signal intensity data is a crucial piece of information. This has been illustrated earlier in the first GWAS of T1D. 8, 64 The need for these data has also been shown to be critical in a recent T1DGC experiment, the MHC Fine Mapping project, in which inspection of the SNP signal intensities eliminated nine SNPs that were apparently associated with T1D despite having filtered the data by several conservative QC criteria. 45 Despite all other QC procedures imposed, there remained inconsistent associations between platforms, which in some instances was sufficient to cause a difference in interpretation of results. For example, rs231727 at CTLA4 was the most associated SNP using Illumina but was not associated at the level considered significant for this study in the Sequenom data. One possible explanation for these discrepancies may be the calling algorithms that affect the clustering of the genotype data. Genotype scoring from high throughput technologies cannot be treated as a fully automated process because even the best clustering algorithms will cluster data inappropriately in some circumstances, causing incorrect scoring and very often, these are the SNPs that will have inflated test statistics (low P values) and are false-positive associations.
Further work has been indicated with respect to the analysis of several gene regions. Specifically, the age-atdiagnosis effect at INS requires further investigation. The rs689 (À23HphI) polymorphism was associated with antiinsulin autoantibodies (P ¼ 3.7 Â 10
À5
). 65, 66 These autoantibodies are rarely found in older onset T1D cases. In the T1DGC ASP families, homozygosity for the protective T allele at rs689 delayed diagnosis of T1D by 1.7 year and the frequency of the T allele was 0.02 higher in those diagnosed with T1D over 10 year than those diagnosed at 10 year or less. Combined with the previous findings, 65, 66 these results are consistent with the hypothesis that the T allele at rs689 delays the onset of T1D. However, the age-at-diagnosis effect, although associated at P ¼ 0.001, is not observed in the JDRF/WT case series (P ¼ 0.32, unpublished data, n ¼ 900 cases diagnosed 412 year). This difference could be attributable to ascertainment (ASP families vs isolated cases) or different distributions of age-at-diagnosis in the T1DGC families (mean age-at-diagnosis ¼ 11.8 year, with 1300 diagnosed 412 year) compared with the JDRF/WT case series (mean age-at-diagnosis ¼ 7.8 year).
The CTLA4 locus requires extensive re-sequencing, and then genotyping in a large number of subjects (a minimum of 4000 cases and 4000 controls or 4000 trio families) to find realistic effect sizes (as small as 1.15) and any potential additional independent effects. This study, in contrast to an earlier report in 3671 families, 28 was insufficiently powered (around 60%) for effect sizes of this magnitude. The power provided by the T1DGC families was much higher (99%) to find larger effects (relative risk ¼ 1.5) and, as a result, the association identified by others in the literature of rs2476601 at PTPN22 has been confirmed. Although evidence for a locus with a possible independent effect at PTPN22 (rs1539438) has been identified, this effect was only found in the Illumina dataset. The effect was not replicated in over 8000 cases and 9000 controls and so is probably a false association. The data from the T1DGC ASP families failed to identify consistent evidence for association of the other 14 candidate genes tested with T1D. Although there could still be associations with other SNPs in these gene regions with T1D, generation of convincing support will require analysis of much larger datasets. There remains the possibility that loci (for example, SUMO4
67
) could be associated with T1D in non-European populations. However, such non-European sample sets will have to be as large as the T1DGC data and controlled for population stratification effects if convincing associations are to be obtained.
Materials and methods

Subjects
A total of 2300 families of two parents and two T1D-affected offspring were used for this T1DGC study. The families were ascertained from nine cohorts-Asia Pacific (AP; 191), North America (NA; 334), HBDI (431), Joslin (JOS; 112), Europe (EUR; 475), Sardinia (SAR; 78), UK (114), Diabetes UK WARREN 1 (BDA; 418) and Denmark (DAN; 147). The AP, EUR, NA and UK collections were recruited specifically for the T1DGC study; the remainder were contributed to the T1DGC from established collections. All subjects were asked to give their primary, secondary and tertiary ethnic group, and these were cross-referenced between parents and offspring. Families with inconsistencies were eliminated (60 families: 18 AP; 36 NA; 1 EUR; 5 UK), so that the statistical analysis was confined to families of European origin and white ethnicity.
Genotyping QC
The Insulin SNP, rs689 (À23HphI) was genotyped using a reverse dot-plot genotyping method. 32 Given that SNP genotyping for other genes were performed as part of the same experiment, QC measures were applied to these SNPs collectively. SNPs were genotyped on two platforms, Illumina (GoldenGate) and Sequenom (iPLEX). A total of 350 SNPs were genotyped using the Sequenom platform and 334 SNPs using Illumina. The 16 additional SNPs genotyped on Sequenom represent DNA 'fingerprinting' SNPs. Genotype calling was performed by the T1DGC Genotyping Laboratory (Broad Institute of Harvard/MIT) and QC procedures implemented by the Coordinating Center for the T1DGC (Wake Forest University); however, further QC analyses were performed. For this experiment, only genotype data and not the intensity data from the genotyping platform were provided. As a result, not all QC procedures could be implemented.
A total of 1477 samples did not have SNP data for any of the 684 SNPs (over both platforms); these samples were eliminated from the analyses. An additional 322 samples failed all SNPs on Sequenom and 401 samples failed all SNPs on Illumina. In total, genotype data for 9682 samples were analyzed that had data on one of the genotyping platforms.
Nineteen SNPs had no genotyping data from the Illumina platform and 20 SNPs had no genotyping data from Sequenom. The data from all 39 SNPs were removed from these analyses. Genotype call rate information was not provided, so in the absence of this information, the percentage of missing data was used. A minimum missing data rate of 5% was adopted (equivalent to a 95% call rate) for each platform to meet an appropriate genotyping threshold. Five SNPs (rs1217414, rs2239179, rs2853564, rs3212227, rs3761548) had low call rates with Sequenom and seven SNPs (rs10747524, rs1775759, rs2070762, rs3842748, rs712701, rs7135579, rs791589) had low call rate with Illumina and so were not tested for association with T1D.
Concordance of genotyping between platforms was checked for the 284 SNPs remaining that were common to both platforms. A total of 232 SNPs had greater than 99% concordance between platforms. Five SNPs with o95% concordance were deleted (rs10905669, rs12722486, rs1805012, rs237032, rs797532). Any SNP that significantly deviated from Hardy Weinberg Equilibrium in the parents (Po0.001) was eliminated (14 SNPs on Sequenom and 3 SNPs on Illumina). On the Illumina platform, 23 SNPs had a MAF of o5%; 21 of these also had a MAF of o5% on the Sequenom platform. In total, 57 SNPs genotyped on the Illumina platform were eliminated from analyses, resulting in a dataset of 277 SNPs to be tested for association with T1D. On the Sequenom platform, 64 SNPs were eliminated, resulting in 286 SNPs to be tested for association with T1D. A total of 248 SNPs were common to both platforms.
Statistics
Sets of cases and matched pseudo-controls (consisting of the three genotypes that could have been transmitted to offspring but were not) were generated and analyzed using conditional logistic regression. 68 SNPs were coded as 0, 1 and 2, representing the genotypes 1/1, 1/2 and 2/2. A likelihood ratio test was used to test non-multiplicative effects by including a 'dominance' term (coded 0.5, À0.5 and 0.5) in the regression model and estimating its additional effect. SNPs on the X chromosome were analyzed by coding them as three alleles, the two observed alleles and the 'missing allele' in males. The effect of the X chromosome SNP is tested by likelihood ratio test, comparing a conditional logistic regression model with the three alleles to a conditional logistic regression model with just the missing allele (a one degree of freedom test).
Age-at-diagnosis effects were tested in affected individuals by regressing age-at-diagnosis on genotype (coded as above), stratifying by cohort and clustering within family. Huber/White sandwich estimators were used to account for non-independence within families. Sex effects were tested using a logistic regression model in which sex was used as the outcome variable, genotype was coded as above and Huber/White sandwich estimators used to account for the non-independence
